8-K: Praxis Advances Ulixacaltamide to FDA Pre-NDA Meeting

Praxis Precision Medicines announced a Type B meeting with the FDA for ulixacaltamide in Q4 2025, following positive Essential3 topline results, and updated its corporate presentation.

Summary

• A Type B meeting with the U.S. Food and Drug Administration (FDA) for ulixacaltamide has been granted and is scheduled for the fourth quarter of 2025, following the FDA's review of the Essential3 topline results.
• The corporate presentation was updated for use in meetings with investors, analysts, and others, and is available on the company's website.
• The company's pipeline includes assets in late-stage clinical development with clinical readouts expected in the next four quarters.
• Cash runway is projected into 2028.
• Ulixacaltamide's Essential3 program, targeting Essential Tremor, is reported as the first successful Phase 3 program for a drug in this indication, with both Study 1 and Study 2 meeting their primary endpoints.
• Vormatrigine, for Focal Onset Seizures & Generalized Epilepsy, showed a 56% median seizure reduction from baseline in an 8-week RADIANT Phase 2 study cohort, with 14% of patients seizure-free for the entire 8 weeks.
• Relutrigine, for Developmental & Epileptic Encephalopathies (DEEs), demonstrated sustained seizure reduction, with a median reduction of up to 90% by Month 11 in the EMBOLD Cohort 1 study, and a mean longest period without seizures of 67 days.
• Elsunersen, for SCN2A GoF DEE, showed a mean 39% and median 43% reduction in seizures, and a mean 52% and median 48% increase in seizure-free days in EMBRAVE Part 1 (N=4).

Sentiment

Score: 8

Explanation: The company reported positive topline results for its lead Essential Tremor candidate, ulixacaltamide, leading to an FDA Type B meeting, a critical step towards NDA submission. Strong efficacy data was also presented for its epilepsy pipeline (vormatrigine, relutrigine, elsunersen), coupled with a cash runway into 2028, indicating robust operational and clinical progress across multiple programs.

Positives

• Ulixacaltamide's Essential3 program successfully met primary endpoints in both Study 1 and Study 2, demonstrating significant efficacy in Essential Tremor.
• The FDA granted a Type B meeting for ulixacaltamide in Q4 2025, indicating regulatory progress towards a potential New Drug Application (NDA).
• Ulixacaltamide was generally well tolerated in studies, with no drug-related serious adverse events (SAEs).
• Vormatrigine's RADIANT Phase 2 study showed strong efficacy with a 56% median seizure reduction in focal epilepsy patients and rapid response, de-risking future pivotal studies.
• Relutrigine's EMBOLD Cohort 1 demonstrated sustained and robust seizure reduction (up to 90% median) and meaningful improvements in patient well-being, with no drug-related SAEs or dose reductions required.
• Elsunersen's EMBRAVE Part 1 showed clinically meaningful seizure reduction and increased seizure-free days in SCN2A GoF DEE patients, with no study drug-related adverse events.
• The company maintains a cash runway into 2028, providing financial stability for ongoing and future development programs.
• The pipeline includes multiple assets with upcoming clinical readouts and regulatory milestones within the next four quarters, indicating active progress across the portfolio.

Negatives

• Ulixacaltamide's most common treatment-emergent adverse events (TEAEs) (>=10%) included constipation, dizziness, euphoric mood, brain fog, headache, paraesthesia, and insomnia.
• Discontinuations in ulixacaltamide studies were primarily due to adverse events, with dizziness and brain fog being the most common reasons.

Risks

• Uncertainties inherent in clinical trials, including their success and timing.
• Risks related to the expected timing of submission for regulatory approval or review by governmental authorities.
• Ability to obtain and maintain regulatory approval of any product candidates.
• Ability to establish manufacturing capabilities and collaboration partners' abilities to manufacture product candidates and scale production.
• Potential addressable market sizes for product candidates may differ from estimates.
• New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

Future Outlook

The company anticipates a pre-NDA meeting with the FDA for ulixacaltamide in Q4 2025, aiming for regulatory submission. Upcoming clinical milestones include topline results for vormatrigine's RADIANT study in Q4 2025, and for relutrigine's EMBOLD Cohort 2 and elsunersen's EMBRAVE Part A in 1H 2026. Enrollment completion for several pivotal trials and candidate declarations for preclinical assets are also expected through 2026, reflecting a robust and active development pipeline.

Management Comments

• Our four pillars guide how we develop medicines: focus on therapeutic targets identified through human genetics, utilize translational tools to validate target potential and provide early proof of biology, employ efficient and rigorous clinical development paths to proof-of-concept, and implement patient-guided development strategies.
• We are positioned to bring innovation to patients with CNS disorders, with assets in late-stage development and a cash runway into 2028.

Industry Context

The company operates in the highly specialized and competitive central nervous system (CNS) disorder market, focusing on areas with significant unmet medical needs such as Essential Tremor and various forms of epilepsy. Its strategy of leveraging human genetics and precision medicine platforms (Cerebrum for small molecules and Solidus for ASOs) aligns with broader industry trends towards targeted therapies. The substantial market opportunities identified for its epilepsy portfolio (Vormatrigine >$2.5B, Relutrigine >$3B, Elsunersen >$500M) underscore the commercial potential within these therapeutic areas.

Comparison to Industry Standards

• Ulixacaltamide's Essential3 program is highlighted as the 'First Successful Program in Essential Tremor,' suggesting a leading position in this indication, though specific comparative data against other investigational or approved treatments were not provided in the filing.
• Vormatrigine is positioned to offer 'Best-in-disease efficacy' and 'Superior Efficacy' compared to standard of care anti-seizure medications (ASMs), with claims of ideal tolerability and limited drug-drug interactions, but specific comparative trial data against named competitor drugs were not detailed in the filing.
• Relutrigine is presented with 'Potential for class leading efficacy and tolerability' in DEEs, based on its differentiated profile and consistent efficacy across diverse DEE models, without direct comparative data against specific competitor therapies in the filing.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, regulatory milestones, and a strong pipeline, potentially leading to increased share value.
• Patients: Potential for new, effective treatments for debilitating CNS disorders like Essential Tremor and various epilepsies, addressing significant unmet medical needs.
• Employees: Continued stability and growth opportunities within the company as development programs advance.
• Regulatory Authorities: Engagement with the FDA through a Type B meeting for ulixacaltamide demonstrates adherence to regulatory pathways and progress towards market authorization.

Next Steps

• Hold a Pre-NDA meeting with the FDA for ulixacaltamide in Q4 2025.
• Release full cohort topline results for Vormatrigine's RADIANT Phase 2 study in Q4 2025.
• Finalize Vormatrigine's POWER1 Phase 2/3 study in Q4 2025.
• Declare candidates for PRAX-080 (PCDH19) and PRAX-090 (SYNGAP1) by year-end 2025.
• Declare candidate for PRAX-100 (SCN2A Autism) by mid-2025.
• Initiate Vormatrigine's POWER3 monotherapy study in 1H 2026.
• Release topline results for Relutrigine's EMBOLD Cohort 2 (SCN2A GoF and SCN8A) in 1H 2026.
• Release topline results for Elsunersen's EMBRAVE Part A (Phase 1/2) in 1H 2026.
• Complete enrollment for Vormatrigine's POWER2 Phase 2/3 study in 2026.
• File NDA for Relutrigine in 2026.
• Complete enrollment for Relutrigine's EMERALD (Broad DEEs) study in 2026.
• Complete enrollment for Elsunersen's EMBRAVE3 registrational trial in 2026.

Key Dates

Recommendation

The company has demonstrated significant clinical progress with its lead candidate, ulixacaltamide, achieving positive topline results in the Essential3 program and securing a Type B meeting with the FDA, signaling a clear path towards regulatory submission. Additionally, other pipeline assets like vormatrigine, relutrigine, and elsunersen have shown promising efficacy data, de-risking the broader portfolio. A cash runway extending into 2028 provides financial stability to advance these programs. These developments collectively represent substantial value creation and a strong investment opportunity.

Keywords

Praxis Precision Medicines, Ulixacaltamide, Essential Tremor, FDA, Type B Meeting, Vormatrigine, Epilepsy, Focal Onset Seizures, Generalized Epilepsy, Relutrigine, Developmental Epileptic Encephalopathies, DEE, Elsunersen, SCN2A GoF DEE, Clinical Trials, Neuroscience, Pharmaceuticals, Drug Development